Citations 13
Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury–Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant
Dandoy, Christopher E. , Ahn, Kwang Woo , Brown, Valerie I. , Dvorak, Christopher C. , Farhadfar, Nosha , Ganguly, Siddartha, Hale, Gregory A., Hashmi, Shahrukh K. , Hematti, Peiman , Martino, Rodrigo , Nusrat, Roomi , Olsson, Richard F. , Rotz, Seth J. , Sung, Anthony D. , Lindemans, Caroline A. , Riches, Marcie , Olsson, Richard F , Martino, Rodrigo , Dvorak, Christopher C , Dandoy, Christopher E , Hematti, Peiman , Sung, Anthony D , Kim, Soyoung , Chen, Min , Ardura, Monica I. , Chhabra, Saurabh , Díaz, Miguel Ángel , Flagg, Aron , Nishihori, Taiga , Perales, Miguel‐Angel , Komanduri, Krishna V.
JAMA Network Open | January 8, 2020 | Volume: 3 | Issue: 1 | Pages: e1918668
Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1
Üstün, Celalettin , Kim, Soyoung , Chen, Min , Beitinjaneh, Amer , Brown, Valerie I. , Daly, Andrew , Freytes, César O. , Ganguly, Siddhartha , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Olsson, Richard F. , Page, Kristin , Saad, Ayman , Seo, Sachiko , William, Basem M. , Wirk, Baldeep , Auletta, Jeffery J. , Lindemans, Caroline A. , Riches, Marcie , Freytes, Cesar O , Hashmi, Shahrukh K , Hildebrandt, Gerhard C , Lazarus, Hillard M , Nishihori, Taiga , Olsson, Richard F , Saad, Ayman , Yared, Jean A , Komanduri, Krishna V , Riches, Marcie L , William, Basem , Dahi, Parastoo B , Díaz, Miguel Ángel , Lazarus, Hillard M. , Nishihori, Taiga , Papanicolaou, Genovefa A. , Wingard, John R. , Yared, Jean A. , Perales, Miguel‐Angel , Komanduri, Krishna V. , Auletta, Jeffery J , Kim, Soyoung
Blood Advances | August 30, 2019 | Volume: 3 | Issue: 17 | Pages: 2525-2536
10.1182/bloodadvances.2019000226
Abstract Presumably, reduced-intensity/nonmyeloablative conditioning (RIC/NMA) for allogeneic hematopoietic cell transplantation (alloHCT) results in reduced infections compared with myeloablative conditioning (MAC) regimens; however, published evidence is limited. In this Center for International Blood and Marrow Transplant Research study, 1755 patients (aged ≥40 years) with acute myeloid leukemia in first complete remission were evaluated for infections occurring within 100 days after T-cell replete alloHCT. Patients receiving RIC/NMA (n = 777) compared with those receiving MAC (n = 978) were older and underwent transplantation more recently; however, the groups were similar regarding Karnofsky performance score, HCT–comorbidity index, and cytogenetic risk. One or more infections occurred in 1045 (59.5%) patients (MAC, 595 [61%]; RIC/NMA, 450 [58%]; P = .21) by day 100. The median time to initial infection after MAC conditioning occurred earlier (MAC, 15 days [range, <1-99 days]; RIC/NMA, 21 days [range, <1-100 days]; P < .001). Patients receiving MAC were more likely to experience at least 1 bacterial infection by day 100 (MAC, 46% [95% confidence interval (CI), 43-49]; RIC/NMA, 37% [95% CI, 34-41]; P = .0004), whereas at least a single viral infection was more prevalent in the RIC/NMA cohort (MAC, 34% [95% CI, 31-37]; RIC/NMA, 39% [95% CI, 36-42]; P = .046). MAC remained a risk factor for bacterial infections in multivariable analysis (relative risk, 1.44; 95% CI, 1.23-1.67; P < .0001). Moreover, the rate of any infection per patient-days at risk in the first 100 days (infection density) after alloHCT was greater for the MAC cohort (1.21; 95% CI, 1.11-1.32; P < .0001). RIC/NMA was associated with reduced infections, especially bacterial infections, in the first 100 days after alloHCT.
Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants
Kumar, Anita J. , Hemmer, Michael, Arora, Mukta , Pidala, Joseph A. , Couriel, Daniel R. , Aljurf, Mahmoud , Cahn, Jean‐Yves, Cairo, Mitchell S. , Farhan, Shatha , Hale, Gregory A., Hashmi, Shahrukh K. , Inamoto, Yoshihiro , Kamble, Rammurti T., Kharfan‐Dabaja, Mohamed A. , MacMillan, Margaret L. , Marks, David I. , Norkin, Maxim , Ringdén, Olle , Schouten, Harry C. , Solh, Melhem , Urbano-Ispizúa, Álvaro , Verdonck, Leo F. , Hamilton, Betty K. , Majhail, Navneet S. , Loren, Alison W. , Ringden, Olov , Majhail, Navneet S , Kim, Soyoung , Spellman, Stephen R. , Alousi, Amin Majid , Cahn, Jean‐Yves , Cutler, Corey S. , Gergis, Usama , Nakasone, Hideki , Qayed, Muna , Schultz, Kirk R. , Teshima, Takanori , Gale, Robert Peter
Blood Advances | May 8, 2018 | Volume: 2 | Issue: 9 | Pages: 1022-1031
10.1182/bloodadvances.2017013052
Key Points Compared with parous female sibling donors, male URDs confer more aGVHD in all patients and more cGVHD in females. There was no difference in survival, relapse, or transplant mortality between recipients of parous female sibling or male URD grafts.